Compare Novo Nordisk A/S (NVO) vs S&P500 ETF (SPY) Price & Performance

Novo Nordisk A/STrade

S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs S&P500 ETF — how do they compare? Novo Nordisk A/S trades at $44.73 (market cap $200.69B), while S&P500 ETF trades at $764.79. The key difference: Novo Nordisk A/S pays a 3.98% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	NVO	SPY
Market Cap	$200.69B	—
Sector	Health	—
52-Week High	$63.98	$777.82
52-Week Low	$35.29	$631.99
Enterprise Value	$215.49B	—
Dividend Yield	3.98%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.

NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.

S&P500 ETF

SPY trades at $766.00, down 0.55% on the day, with a neutral technical signal and bullish moving averages. Support levels are near $760, while resistance sits at $769. The ETF shows no available valuation ratios like P/E or P/B in the data. A dividend of $1.90 is scheduled for payment on July 31, 2026.

Outlook remains mixed amid market volatility from geopolitical tensions and oil price surges. Risks include Fed rate-hike concerns and high valuations, but AI-driven earnings growth offers potential upside. Investors should weigh resilience against near-term headwinds for long-term positioning.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 2 days agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

SPY

Memory chip stocks rise as Goldman Sachs says sector's worst downturn may be over.24/7 Wall Street · 19 hours agoBullish S&P 500 set to rebound with 8,000 target despite rising rates, driven by strong earnings growth.Seeking Alpha · 20 hours agoBullish Safe bond funds lost money over 5 years, showing cautious investing can be risky for young investors.24/7 Wall Street · 20 hours agoNeutral View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.